Drugs Containing Excipient (Inactive Ingredient) ALANINE

« Back to Dashboard

Generic drugs containing ALANINE excipient

Company	Ingredient	NDC	Excipient
GRIFOLS USA LLC	alpha1-proteinase inhibitor (human)	13533-705	ALANINE
Takeda Pharmaceuticals America Inc	human c1-esterase inhibitor	42227-081	ALANINE
CellTrans Inc	donislecel	73539-001	ALANINE

Alanine Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 5, 2026

Alanine is a low-cost, fermentation-derived amino acid used in pharmaceutical formulations, parenteral nutrition, biologic media, and selected oral products. Its market is driven more by volume growth, manufacturing efficiency, and quality compliance than by patent exclusivity. Public companies generally report alanine within broader amino-acid, pharmaceutical-ingredient, or nutrition segments, so no reliable standalone global revenue figure exists.

The financial outlook is moderately positive but low-margin. Demand should track injectable drug production, biologics manufacturing, clinical nutrition, and pharmaceutical-grade excipient substitution. Pricing power is limited because alanine is a relatively simple molecule with multiple manufacturing routes and qualified suppliers.

What is alanine and how is it used as a pharmaceutical excipient?

Alanine is an alpha-amino acid with the molecular formula C3H7NO2. L-alanine is the naturally occurring enantiomer and the form most relevant to pharmaceutical and nutritional applications. The CAS Registry Number for L-alanine is 56-41-7.

Alanine can function as:

• A stabilizing amino acid in pharmaceutical formulations.
• A component of parenteral nutrition solutions.
• An osmolality or tonicity contributor in selected injectable products.
• A nutrient or cell-culture component in biologics manufacturing.
• A formulation component in oral and specialty dosage forms.
• A processing or bulking ingredient in certain pharmaceutical manufacturing systems.

Its commercial role varies by product. In some applications, alanine is a true inactive ingredient. In parenteral nutrition, it may be treated as a nutritional active component rather than a conventional excipient.

What grades of alanine are sold?

Grade	Principal use	Typical commercial requirement
Food grade	Nutrition and food processing	Food-compliance specifications
Pharmaceutical grade	Drug products and clinical nutrition	USP-NF, Ph. Eur., GMP and impurity controls
Bioprocess grade	Cell culture and biologics manufacturing	Low bioburden, trace-metal, endotoxin and consistency controls
Research grade	Laboratory use	High chemical purity but not necessarily GMP-qualified
Industrial grade	Chemical and technical applications	Lower regulatory burden and broader impurity profile

Pharmaceutical buyers generally require control of assay, identity, water, residue on ignition, related substances, elemental impurities, microbial quality, and batch-to-batch consistency. The applicable standard depends on the market and product.

How large is the pharmaceutical alanine excipient market?

No authoritative public source isolates global pharmaceutical alanine excipient revenue from broader amino-acid or pharmaceutical excipient sales. Market reports that publish a standalone alanine figure often combine food, feed, nutrition, pharmaceutical, and industrial uses, making their pharmaceutical-excipient estimates unsuitable for investment-grade analysis.

The market should be evaluated through demand pools rather than a single headline value:

Demand pool	Commercial relevance	Growth profile
Parenteral nutrition	Established volume market	Low to moderate growth
Small-molecule injectables	Uses depend on formulation design	Moderate growth
Biologics and cell culture	Quality-sensitive, higher-value demand	Moderate to high growth
Oral pharmaceuticals	Selective use	Low to moderate growth
Clinical-trial supply	Small volume, high qualification burden	Variable
Food and sports nutrition	Large but outside the excipient market	Moderate growth
Animal nutrition	Large volume, price-sensitive	Moderate growth

Pharmaceutical demand is likely a minority of total alanine consumption by volume. The pharmaceutical segment can still generate above-average value because customers pay for GMP systems, regulatory documentation, validated supply chains, and low-contamination production.

What drives alanine excipient demand?

The principal demand drivers are:

1. Growth in injectable drug manufacturing.
2. Expansion of parenteral nutrition.
3. Increased biologics and cell-culture production.
4. Outsourcing to contract development and manufacturing organizations.
5. Preference for fermentation-derived amino acids.
6. Supplier diversification after pharmaceutical supply disruptions.
7. Greater use of excipient risk assessments and qualified alternative sources.

Alanine demand is less exposed to direct-to-consumer prescription trends than an active pharmaceutical ingredient. It is linked to production volumes across many products.

What is the financial trajectory for pharmaceutical alanine?

The financial trajectory is best characterized as volume-led, margin-sensitive growth.

Base-case trajectory

Period	Expected market condition	Financial implication
Near term	Stable demand from established formulations and nutrition products	Revenue growth tracks production volumes
Medium term	Higher biologics, injectable and bioprocess demand	Better mix and qualification revenue
Longer term	Capacity additions and supplier competition	Volume growth with limited price expansion

Alanine is unlikely to become a high-margin specialty excipient solely because of its chemistry. Economic value is concentrated in the manufacturing platform and quality system. A supplier with validated pharmaceutical capacity can earn better margins than a bulk producer even when the underlying molecule is commoditized.

What determines alanine pricing?

The main price variables are:

• Fermentation yield.
• Glucose and other carbon-source costs.
• Energy prices.
• Plant utilization.
• Purification and drying costs.
• Packaging and controlled storage.
• Testing for trace metals, endotoxins and microbial contaminants.
• Qualification costs for new suppliers.
• Freight and regional inventory.
• Currency movements.
• Customer-specific audit and documentation requirements.

Commodity alanine pricing is more sensitive to plant utilization and raw-material costs than to intellectual-property rights. Pharmaceutical-grade pricing has a compliance premium, but that premium can narrow when buyers qualify multiple sources.

Which companies supply pharmaceutical-grade alanine?

The global supply base includes amino-acid manufacturers, pharmaceutical excipient suppliers, specialty chemical distributors, and regional fermentation producers. Major amino-acid companies with relevant capabilities include Ajinomoto, Kyowa Hakko Bio, Evonik, and other regional manufacturers. The exact list of qualified pharmaceutical suppliers depends on geography, grade, dosage form, and customer audit status.

Supplier category	Competitive advantage	Limitation
Large fermentation companies	Scale, process control and global quality systems	Less flexible for small customers
Pharmaceutical ingredient specialists	Documentation, regulatory support and smaller batch capability	Higher unit cost
Regional producers	Pricing and local delivery	May require deeper customer qualification
Distributors	Inventory, logistics and market access	Dependence on upstream manufacturer
Custom manufacturers	Bespoke specifications and supply agreements	Limited scale

Ajinomoto’s amino-acid business illustrates the importance of fermentation scale and integrated production. Kyowa Hakko Bio operates in pharmaceutical and biopharmaceutical raw materials, including amino acids. Evonik has broader amino-acid and pharmaceutical-ingredient capabilities, particularly in specialty and nutrition markets. Supplier participation does not establish that every company sells alanine in every pharmaceutical jurisdiction or dosage form.

What FDA regulatory status applies to alanine?

Alanine is not generally regulated as a drug active ingredient when used as an inactive formulation component. Its regulatory status depends on the product, route of administration, concentration, and intended function.

The principal U.S. regulatory references are:

• FDA Inactive Ingredient Database for precedent in approved drug products.
• USP-NF monograph requirements where applicable.
• Current good manufacturing practice requirements under 21 C.F.R. Parts 210 and 211.
• Product-specific quality and stability data.
• FDA review of the finished dosage form.

The FDA Inactive Ingredient Database is the relevant source for determining whether a specific route and dosage form have precedent. Presence in the database does not automatically authorize every concentration or formulation. The applicant remains responsible for demonstrating product quality and safety.

For injectable products, the regulatory burden is materially higher. Sterility assurance, endotoxin control, particulate control, container compatibility, and impurity management can determine whether a supplier is commercially acceptable.

What is the European regulatory position?

In Europe, alanine used as an excipient is assessed under the finished product authorization and applicable European Pharmacopoeia requirements. Manufacturers must address excipient quality, supplier qualification, contamination risks, and pharmaceutical development in line with European Medicines Agency expectations.

The European Commission’s guideline on excipients in the dossier for medicinal products requires information on excipient function, quality, safety, and control strategy. The ICH quality framework also supports risk-based control of excipients and manufacturing inputs. [1][2][3]

What patents protect alanine as a pharmaceutical excipient?

No composition-of-matter patent can provide meaningful exclusivity over alanine itself. Alanine is an established amino acid, and the molecule is available from multiple commercial producers.

Patent protection may instead apply to:

• Fermentation organisms.
• Genetically modified production strains.
• Metabolic-pathway engineering.
• Recovery and purification processes.
• Crystallization or particle-size control.
• Low-endotoxin manufacturing.
• Pharmaceutical formulations containing alanine.
• Specific biologic media or cell-culture compositions.
• Combination formulations with other amino acids.
• Manufacturing equipment or process controls.

These rights are usually narrower than a drug patent covering a novel active molecule. They may protect a supplier’s cost position or a specific formulation but generally do not block independent production of alanine.

How strong is the patent estate for alanine?

Patent layer	Strength for alanine excipient economics
Alanine molecule	Very weak or nonexistent as a current exclusivity right
General fermentation production	Limited because alternative routes and strains exist
Specific engineered strain	Potentially meaningful if claims are narrow and enforceable
Purification process	Moderate if the process materially improves pharmaceutical quality
Finished formulation	Product-specific and dependent on claim scope
Bioprocess media	Potentially meaningful but usually not alanine-specific
Manufacturing know-how	Often more important than patents

The principal barrier is usually know-how, validated process capability, and regulatory qualification rather than a blocking patent.

When does alanine lose exclusivity?

Alanine does not have a branded-drug exclusivity timeline comparable to a new molecular entity. It has no standard Orange Book exclusivity period as an excipient, and there is no single alanine patent expiration date that controls market entry.

The relevant exclusivity analysis is product-specific:

• A finished drug may have formulation or method-of-use patents that include alanine.
• A biologic may have manufacturing or formulation rights that reference alanine-containing media.
• A supplier may hold process patents with different expiration dates.
• Regulatory exclusivity belongs to the finished product, not to alanine as a raw material.

This distinction is important for diligence. A patent claim covering a drug formulation containing alanine does not create exclusivity over the excipient market.

What is the Orange Book status of alanine?

Alanine itself has no Orange Book listing because the Orange Book identifies approved drug products, active ingredients, therapeutic equivalence information, and certain patent and exclusivity data for finished pharmaceutical products. It is not a registry of excipients.

A finished drug containing alanine may appear in the Orange Book, but alanine would normally be identified as an inactive ingredient in the product’s labeling or FDA product information rather than as the protected active ingredient. [4]

Are there Paragraph IV challenges involving alanine?

There is no standalone Paragraph IV pathway for alanine as an excipient. Paragraph IV litigation concerns an abbreviated new drug application that challenges listed patents for a reference drug. A generic applicant could challenge a formulation patent that includes alanine, but the dispute would concern the finished drug, not alanine as a molecule.

Potential litigation issues include:

• Whether alanine is necessary to practice a claimed formulation.
• Whether the generic product uses the same concentration or excipient combination.
• Whether a formulation claim is properly listed in the Orange Book.
• Whether the patent claims a method of use rather than the excipient itself.
• Whether a design-around removes alanine or changes its concentration.

The commercial risk is therefore product-specific and cannot be inferred from alanine demand or supplier market share.

What formulation patents may protect alanine-containing products?

Alanine can appear in patent claims directed to:

• Protein stabilization.
• Lyophilized biologic formulations.
• Injectable amino-acid mixtures.
• Cell-culture media.
• Controlled osmolality formulations.
• Freeze-drying cycles and cake structure.
• Reduced aggregation or improved storage stability.
• Combination excipient systems containing sugars, buffers, surfactants and amino acids.

In biologics, alanine may be one component in a broader formulation claim. The enforceability of such a claim depends on concentration ranges, claim construction, written description, enablement, formulation performance, and evidence of infringement.

Alanine does not automatically create a patent barrier. The relevant question is whether the product falls within a valid claim covering the complete formulation or manufacturing process.

How does alanine compare with other amino-acid excipients?

Excipient	Common formulation role	Relative commercial profile
Alanine	Stabilizer, nutrient, formulation component	Low-cost, broad supply base
Glycine	Stabilizer, bulking agent, buffer-related use	Highly established and commoditized
Arginine	Protein stabilization and solubility support	Higher value in biologics
Histidine	Buffer and protein formulation support	Stronger biologics linkage
Proline	Stabilization and bioprocess use	More specialized
Methionine	Oxidation control in biologic formulations	Specialty demand
Phenylalanine	Nutrition and media applications	More nutrition-linked
Glutamine	Cell culture and nutrition	Degradation and stability considerations

Alanine has less formulation differentiation than histidine or arginine in many biologic applications. Its advantages are cost, availability, low chemical complexity, and compatibility with amino-acid systems.

What biosimilar risk affects alanine demand?

Alanine has no direct biosimilar risk because it is not a biologic drug. Biosimilar competition can still affect demand indirectly.

If a reference biologic and its biosimilars use alanine-containing formulations or manufacturing media, increased biosimilar production can expand alanine volume. Conversely, a biosimilar developer may use a different formulation or manufacturing process, reducing demand from a particular product.

The main biosimilar-related commercial variables are:

• Number of approved biosimilars.
• Manufacturing scale.
• Whether the biosimilar matches the reference formulation.
• Supplier qualification requirements.
• Use of alanine in upstream media versus the final drug product.
• Contract manufacturing allocation.

Biologics manufacturing is potentially a higher-value market for pharmaceutical-grade alanine, but it requires more extensive supplier documentation and change-control management than many oral products.

What manufacturing and intellectual-property barriers affect alanine?

Alanine can be produced through fermentation or chemical synthesis. Industrial economics generally favor fermentation for large-scale L-alanine production because it can deliver stereochemical control and a suitable cost structure.

Key barriers include:

• Maintaining consistent fermentation yield.
• Controlling impurities generated by the production strain.
• Removing residual nutrients and process chemicals.
• Achieving pharmaceutical-grade microbial quality.
• Controlling endotoxins for injectable applications.
• Validating cleaning and cross-contamination controls.
• Maintaining supply during plant shutdowns.
• Demonstrating equivalence after process changes.
• Supporting customer audits and regulatory inspections.

Manufacturing know-how can be more commercially important than patent protection. A producer with lower yield, weaker purification, or limited GMP documentation may be unable to compete for injectable or biologics customers even if its chemical assay is acceptable.

What licensing deals and settlement agreements affect alanine?

There is no widely reported, alanine-specific licensing or patent-settlement framework comparable to those surrounding branded pharmaceutical products. Commercial arrangements are more likely to involve:

• Long-term supply agreements.
• Dual-source qualification.
• Contract manufacturing.
• Technology transfer.
• Fermentation-strain licensing.
• Regional distribution rights.
• Quality agreements.
• Customer-specific change-control obligations.

Any litigation settlement involving alanine would likely concern a finished formulation, manufacturing process, or biologic product rather than the amino acid itself. Public disclosure is limited because supply and technology agreements are often confidential.

What generic launch risks exist for drugs containing alanine?

The presence of alanine generally does not create a meaningful generic-entry barrier. A generic applicant may use alanine if the product’s formulation permits it, or may substitute another excipient if the finished product meets applicable requirements.

Generic launch risk depends on:

• Active-ingredient patent expiry.
• Listed formulation patents.
• Method-of-use claims.
• Regulatory exclusivity.
• Bioequivalence requirements.
• Injectable formulation complexity.
• Device or container compatibility.
• Manufacturing process patents.

Alanine supply is unlikely to delay generic entry unless the product requires a highly specific grade, a single-source supplier, or a proprietary alanine-containing formulation.

What geographic markets matter most?

The main geographic markets are the United States, European Union, Japan, China, India, and South Korea.

Region	Market characteristic
United States	Strong FDA documentation and injectable-product demand
European Union	Pharmacopoeial compliance and structured excipient oversight
Japan	High quality expectations and established amino-acid manufacturing
China	Large fermentation base and expanding pharmaceutical production
India	Growing generic and contract-manufacturing demand
South Korea	Biologics and advanced manufacturing demand

Asia is important for production scale and cost. The United States, Europe and Japan remain important for high-compliance pharmaceutical sales. A global supplier generally needs regional regulatory support, local inventory, and reliable change-control communication.

Key Takeaways

• Alanine is a mature, low-cost pharmaceutical excipient and amino-acid ingredient.
• No standalone, authoritative global revenue figure exists for pharmaceutical alanine.
• Financial growth should come from volume, biologics manufacturing, injectable drugs and clinical nutrition.
• Pricing power is limited by multiple suppliers and low molecular complexity.
• The strongest competitive advantages are fermentation yield, pharmaceutical-grade quality systems and supply reliability.
• Alanine has no meaningful molecule-level patent exclusivity.
• Orange Book and Paragraph IV issues apply only to finished drug products containing alanine.
• Biosimilar activity can increase or reduce demand depending on formulation and manufacturing choices.
• Manufacturing know-how and regulatory qualification are more important than composition-of-matter patents.
• The most attractive segment is high-compliance alanine for injectables, biologics and bioprocess applications.

FAQs

Is alanine an active pharmaceutical ingredient or an excipient?

It can be either, depending on the product. In parenteral nutrition, alanine may contribute nutritional value. In a conventional drug formulation, it is generally evaluated as an inactive ingredient.

Is L-alanine safer commercially than D-alanine?

L-alanine has the broader pharmaceutical and nutritional market because it is the naturally occurring enantiomer. D-alanine has more specialized applications and may require a separate regulatory and customer qualification analysis.

Can alanine be replaced by glycine in a pharmaceutical formulation?

Sometimes, but not automatically. Substitution can affect stability, osmolality, pH, aggregation, dissolution, lyophilization behavior and regulatory comparability.

Does alanine qualify for drug patent protection?

Alanine itself does not provide a practical new-molecule patent position. Protection may arise from a specific formulation, production strain, purification process or manufacturing method.

Is pharmaceutical-grade alanine a high-margin product?

Usually not at the molecule level. Margins improve when the supplier provides validated GMP production, injectable-grade controls, reliable documentation, regulatory support and secure regional supply.

References

1. European Medicines Agency. (2011). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.

2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

3. International Council for Harmonisation. (2005). ICH Q8(R2): Pharmaceutical development. ICH.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.